Deshmukh R, Ting DSJ, Elsahn A, et al. - In this retrospective study, researchers reported the real-world experience of using topical ciclosporin, Ikervis, in the management of ocular surface inflammatory diseases (OSIDs). The sample consisted of patients treated with Ikervis for OSIDs at the Queen’s Medical Centre, Nottingham, between 2016 and 2019. Four hundred sixty-three patients were involved; the mean age was 51.1 ± 21.6 years, with a 59.0% female predominance. Dry eye disease, followed by allergic eye disease and ocular mucous membrane pemphigoid/Steven-Johnson syndrome was the most common diagnosis. In a real-world setting, Ikervis is an important steroid-sparing topical treatment for managing OSIDs. To benefit a greater number of patients, more tolerable preparations are needed.